论文部分内容阅读
目的:胰岛素样生长因子-Ⅰ(IGF-Ⅰ)是一种作用于多个组织和器官的多向性蛋白质,具有促进有丝分裂、刺激蛋白质和蛋白多糖的合成、DNA和RNA的合成以及促进细胞增殖和分化的作用。IGF-Ⅰ调节细胞代谢受胰岛素样生长因子结合蛋白(IGFBPs)的调控,通过IGF受体发挥生理作用。肌萎缩侧索硬化(ALS)是一种致死性神经系统疾病,以脊髓、脑干、运动皮层运动神经元逐渐变性丢失为特征。ALS病因不清,目前有许多假说,其中被大多数认可的学说是运动神经元缺乏必需的营养因子,导致神经元变性、丢失以及靶肌肉萎缩。ALS患者的外周和中枢的IGF-Ⅰ系统均有较大改变。IGF-Ⅰ治疗ALS的离体实验和在体实验效果显著,目前多中心正在进行IGF-Ⅰ治疗ALS患者的三期临床试验。
OBJECTIVE: Insulin-like growth factor-I (IGF-I) is a multi-directional protein that acts on multiple tissues and organs and promotes mitosis, stimulating protein and proteoglycan synthesis, DNA and RNA synthesis, and promoting cell proliferation And the role of differentiation. IGF-I regulates cellular metabolism under the regulation of insulin-like growth factor binding proteins (IGFBPs) and exerts physiological effects through IGF receptors. Amyotrophic lateral sclerosis (ALS) is a fatal neurological disorder characterized by gradual loss of motoneurons in the spinal cord, brainstem, and motor cortex. The etiology of ALS is unclear. There are many hypotheses to date. One of the most accepted doctrines is that motor neurons lack the necessary trophic factors, leading to neuronal degeneration, loss, and target muscle atrophy. ALS patients with peripheral and central IGF-Ⅰ system have greatly changed. IGF-Ⅰ treatment of ALS in vitro and in vivo experimental results are remarkable, the current multi-center ongoing IGF-Ⅰ treatment of ALS patients with phase III clinical trials.